Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
about
Targeted anti-vascular therapies for ovarian cancer: current evidenceCombinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current statusProfile of pazopanib and its potential in the treatment of epithelial ovarian cancerPotent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancerUtility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.Bevacizumab and ovarian cancerPotent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.Metronomics as maintenance treatment in oncology: time for chemo-switch.Pazopanib in ovarian cancer.CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models.Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized 13C-Pyruvate MR Spectroscopy and 18F-FDG PET/CT Imaging in a Mouse Model.
P2860
Q26830287-EC04CC9C-1594-48C8-B344-6552467CA93EQ27001560-8793AB2E-4DD2-4682-A829-C9169049077BQ27011840-BE2332B1-13E2-4E36-8EEE-E14FE07EA7D9Q33780751-F75C95BC-33EA-4492-AF2C-6B7A1C32FA08Q33875597-F383C0CD-29A5-453D-9113-886B09641E2FQ35233993-2AD6C23E-9ADE-447B-BCFD-D07A4923A9C0Q35282945-FD2DEC2B-D151-43F7-B894-5029C9D7E55AQ35954103-15DD579C-D8BA-47C8-90CB-4B48A720BAE8Q35966821-80935CFB-18B9-479F-91EB-5C9F8E6CA115Q36163874-DB16F3F4-8AFF-49D2-B37B-BBCAF8C1809CQ36359684-42A850B5-478C-4B5F-8E14-A2BD56C250AAQ36557707-49B6935D-BBF1-492B-A897-009B5AF608D0Q36567390-F7E24B97-D92C-4792-823C-440208E3BC22Q36618871-89022A65-FF53-40F6-A70A-EF645F137760Q37707573-33FA8DF8-720B-4BB4-BD26-DC97E37597E0Q38571120-974B5740-5C15-4A70-87B3-17A5959C26F7Q38891812-0D35BD5D-33C4-4978-8600-8C6C23DEA3D0Q39501053-02D0A08D-51E8-4365-8DB3-9251B9411393Q40999620-CB7A10A9-AEF6-42CF-8B21-AAC992CA671CQ41912972-70E2AB4F-E31A-4FD2-94ED-942FFC21DB88Q47698844-DE6B6C2C-90C8-48EE-A644-DD93271AFB2F
P2860
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Bridging the gap between cytot ...... d pazopanib in ovarian cancer.
@ast
Bridging the gap between cytot ...... d pazopanib in ovarian cancer.
@en
type
label
Bridging the gap between cytot ...... d pazopanib in ovarian cancer.
@ast
Bridging the gap between cytot ...... d pazopanib in ovarian cancer.
@en
prefLabel
Bridging the gap between cytot ...... d pazopanib in ovarian cancer.
@ast
Bridging the gap between cytot ...... d pazopanib in ovarian cancer.
@en
P2093
P2860
P1476
Bridging the gap between cytot ...... nd pazopanib in ovarian cancer
@en
P2093
Alpa M Nick
Amy R Carroll
Anil K Sood
Aparna A Kamat
Chunhua Lu
Melissa Dumble
Mian M K Shahzad
Nicholas Jennings
Rakesh Kumar
Rebecca L Stone
P2860
P304
P356
10.1158/1535-7163.MCT-09-0967
P50
P577
2010-04-06T00:00:00Z